Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

被引：0

作者：

Mittelman, Moshe ^{[1
,7
]}

Platzbecker, Uwe ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Lawniczek, Tomasz ^{[4
]}

Zhu, Zewen ^{[5
]}

Selleslag, Dominik ^{[6
]}

机构：

[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[2] Univ Hosp Leipzig, Med Clin & Polyclin 1, Hematol & Cellular Therapy, Leipzig, Germany

[3] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[4] Novartis Pharm AG, Basel, Switzerland

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] AZ Sint Jan Brugge Oostende AV, Dept Hematol, Brugge, Belgium

[7] Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-6423906 Tel Aviv, Israel

来源：

ACTA HAEMATOLOGICA | 2023年 / 146卷 / 05期

关键词：

Advanced myelodysplastic syndrome; Acute myeloid leukemia; Eltrombopag; Thrombocytopenia; PLACEBO; BLIND; RISK; INTERMEDIATE; ROMIPLOSTIM; MDS;

D O I：

10.1159/000531146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 x 10(9) platelets/L). Approximately 30-65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.

引用

页码：373 / 378

页数：6

共 50 条

[31] Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial [J].

Zhao, Yan ;

Li, Jing-Yi ;

Yang, Bin ;

Ding, Yang-Feng ;

Wu, Li-Ming ;

Zhang, Li-Tao ;

Wang, Jin-Yan ;

Lu, Qian-Jin ;

Zhang, Chun-Lei ;

Zhang, Fu-Ren ;

Zhu, Xiao-Hong ;

Li, Yu-Mei ;

Tao, Xiao-Hua ;

Diao, Qing-Chun ;

Li, Lin-Feng ;

Lu, Jian-Yun ;

Man, Xiao-Yong ;

Li, Fu-Qiu ;

Xia, Xiu-Juan ;

Song, Jiao-Ran ;

Jia, Ying-Min ;

Zhang, Li-Bo ;

Chen, Bo ;

Zhang, Jian-Zhong .

BIODRUGS, 2024, 38 (05) :681-689

[32] Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study [J].

Reshef, Avner ;

Hsu, Connie ;

Katelaris, Constance H. ;

Li, Philip H. ;

Magerl, Markus ;

Yamagami, Keiko ;

Guilarte, Mar ;

Keith, Paul K. ;

Bernstein, Jonathan A. ;

Lawo, John-Philip ;

Shetty, Harsha ;

Pollen, Maressa ;

Wieman, Lolis ;

Craig, Tim J. .

ALLERGY, 2025, 80 (02) :545-556

[33] Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION) : an open-label extension study [J].

Bacharier, Leonard B. ;

Maspero, Jorge F. ;

Katelaris, Constance H. ;

Fiocchi, Alessandro G. ;

Gagnon, Remi ;

de Mir, Ines ;

Guilbert, Theresa W. ;

Jackson, Daniel J. ;

Staudinger, Heribert W. ;

Laws, Elizabeth ;

Mannent, Leda P. ;

Akinlade, Bolanle ;

Maloney, Jennifer ;

Tawo, Kelsey ;

Khokhar, Faisal A. ;

Li, Ning ;

Hardin, Megan ;

Abdulai, Raolat M. ;

Lederer, David J. ;

Robinson, Lacey B. .

LANCET RESPIRATORY MEDICINE, 2024, 12 (01) :45-54

[34] Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux [J].

Deshayes, Samuel ;

Khellaf, Mehdi ;

Zarour, Anissa ;

Layese, Richard ;

Fain, Olivier ;

Terriou, Louis ;

Viallard, Jean-Francois ;

Cheze, Stephane ;

Graveleau, Julie ;

Slama, Borhane ;

Audia, Sylvain ;

Cliquennois, Manuel ;

Ebbo, Mikael ;

Le Guenno, Guillaume ;

Salles, Gilles ;

Bonmati, Caroline ;

Teillet, France ;

Galicier, Lionel ;

Lambotte, Olivier ;

Hot, Arnaud ;

Lefrere, Francois ;

Mahevas, Matthieu ;

Canoui-Poitrine, Florence ;

Michel, Marc ;

Godeau, Bertrand .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) :1314-1324

[35] Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes [J].

Lalayanni, Chrysavgi ;

Demosthenous, Christos ;

Iskas, Mihcail ;

Kelaidi, Charikleia ;

Papathanasiou, Maria ;

Syrigou, Antonia ;

Athanasiadou, Anastasia ;

Papalexandri, Apostolia ;

Batsis, Ioannis ;

Vardi, Anna ;

Polychronopoulou, Sophia ;

Sakellari, Ioanna .

LEUKEMIA & LYMPHOMA, 2022, 63 (13) :3128-3137

[36] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine [J].

Handa, Hiroshi ;

Cheong, June-Won ;

Onishi, Yasushi ;

Iida, Hiroatsu ;

Kobayashi, Yukio ;

Kim, Hyeoung-Joon ;

Chiou, Tzeon-Jye ;

Izutsu, Koji ;

Tsukurov, Olga ;

Zhou, Xiaofei ;

Faessel, Helene ;

Yuan, Ying ;

Sedarati, Farhad ;

Faller, Douglas V. ;

Kimura, Akiko ;

Wu, Shang-Ju .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

[37] Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine [J].

Hiroshi Handa ;

June-Won Cheong ;

Yasushi Onishi ;

Hiroatsu Iida ;

Yukio Kobayashi ;

Hyeoung-Joon Kim ;

Tzeon-Jye Chiou ;

Koji Izutsu ;

Olga Tsukurov ;

Xiaofei Zhou ;

Helene Faessel ;

Ying Yuan ;

Farhad Sedarati ;

Douglas V. Faller ;

Akiko Kimura ;

Shang-Ju Wu .

Journal of Hematology & Oncology, 15

[38] Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia [J].

Tsurusawa, M. ;

Shimomura, Y. ;

Asami, K. ;

Kikuta, A. ;

Watanabe, A. ;

Horikoshi, Y. ;

Matsushita, T. ;

Kanegane, H. ;

Ohta, S. ;

Iwai, A. ;

Mugishima, H. ;

Koizumi, S. .

LEUKEMIA, 2010, 24 (02) :335-344

[39] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial [J].

Zhao, Yan ;

Zhang, Litao ;

Wu, Liming ;

Yang, Bin ;

Wang, Jinyan ;

Li, Yumei ;

Li, Jingyi ;

Diao, Qingchun ;

Sun, Qing ;

Zhu, Xiaohong ;

Man, Xiaoyong ;

Wang, Lihua ;

Li, Linfeng ;

Feng, Yanyan ;

Zeng, Huiming ;

Cai, Tao ;

Ren, Hong ;

Lu, Jianyun ;

Lu, Qianjin ;

Tao, Xiaohua ;

Xiao, Rong ;

Ji, Chao ;

Li, Fuqiu ;

Zhang, Jianzhong .

ALLERGY, 2025, 80 (05) :1348-1357

[40] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study [J].

Smolen, Josef S. ;

Xie, Li ;

Jia, Bochao ;

Taylor, Peter C. ;

Burmester, Gerd ;

Tanaka, Yoshiya ;

Elias, Ayesha ;

Cardoso, Anabela ;

Ortmann, Rob ;

Walls, Chad ;

Dougados, Maxime .

RHEUMATOLOGY, 2021, 60 (05) :2256-2266

← 1 2 3 4 5 →